Business
Brii Bio Presents Late-Breaking Data from Its Ongoing Phase 2 ENSURE Study at EASL Congress 2025, Suggesting BRII-179's Role in Advancing Higher HBsAg Loss
Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical need, today announced data from its ongoing Phase 2 ENSURE study as late-breaking posters at the European Association for the Study of the Liver (EASL) Congress 2025 in Amsterdam, the Netherlands.
About this update from Brii Biosciences Limited
[{"type":"list","items":[{"val":[{"type":"text","content":"End of treatment (EOT) data from Cohort 4 of the ENSURE study suggest that patients responding to prior BRII-179 treatment achieved faster and higher rate of surface antigen clearance with curative treatments compared to BRII-179 naïve participants, strengthening the case for a novel enrichment strategy, utilizing BRII-179 to identify and prime patients for improved functional cure outcomes","length":423,"tagName":"p"}]},{"val":[{"type":"text","content":"24 Week follow-up results from Cohorts 1-3 of the ENSURE study demonstrated sustained off-treatment benefits of elebsiran + PEG-IFNα combination therapy vs PEG-IFNα alone","length":170,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":593,"olType":false},{"type":"text","content":"DURHAM, N.C. and BEIJING, May 8, 2025 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical need, today announced data from its ongoing Phase 2 ENSURE study as late-breaking posters at the European Association for the Study of the Liver (EASL) Congress 2025 in Amsterdam, the Netherlands.","length":474,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Brii Biosciences Limited)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Brii Biosciences Limited)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":105,"url":"https://media.zenfs.com/en/prnewswire.com/a19981213a11806c724bc1d308aaae78"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/V3nK_VGVGa.vonDXTWY9Ug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE4NTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/a19981213a11806c724bc1d308aaae78","width":400,"height":105}},"href":"https://mma.prnewswire.com/media/1690538/Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"ENSURE (NCT05970289) is a multicenter, open-label Phase 2 study. Cohorts 1-3 were designed to evaluate the contribution of elebsiran, an investigational small interfering ribonucleic acid (siRNA), to the combination treatment with pegylated interferon alpha (PEG-IFNα) in participants with chronic HBV infection with baseline hepatitis B surface antigen (HBsAg) of 100-3,000 IU...